Myelofibrosis Market Report and Forecast 2025-2034

Myelofibrosis Market Overview

Myelofibrosis is a rare blood cancer that disrupts the normal production of blood cells in the body. It causes severe bone marrow scarring and reduces the number of blood clotting cells called platelets, leading to weakness and fatigue. There are two types including primary myelofibrosis and secondary myelofibrosis. 

Myelofibrosis Market Growth Drivers

Rising Prevalence of Myelofibrosis Boosts Growth

The rising incidence of the condition is playing an important role in the increasing demand for effective and innovative treatments for the condition. The Leukemia and Lymphoma Society Report 2022-2023 revealed that nearly 157,561 people are living with or in remission from myeloma in the United States. It was estimated that about 35,730 people would be diagnosed with Myeloma in 2023 and approximately 12,590 people are expected to die from myeloma.

Increasing Drug Approvals to Meet Myelofibrosis Market Demand

The market growth is expected to be bolstered by the rising regulatory approvals by the authorities. These approvals play a pivotal role in the availability of the latest treatment drugs and therapies in the market, contributing to enhanced disease management and patient outcomes. For instance, in June 2024, GlaxoSmithKline announced that the Ministry of Health, Labour, and Welfare in Japan has approved momelotinib (Omjjara) for the treatment of patients suffering from myelofibrosis. The regulatory approval was supported by data from the phase 3 MOMENTUM (NCT04173494) and SIMPLIFY-1 (NCT01969838) trials. The approval of momelotinib (Omjjara) is expected to play a crucial role in the treatment of myelofibrosis as it offers a new treatment option, especially for patients with anemia. This could potentially improve patient outcomes and quality of life, triggering competition among the market players. 

Moreover, in January 2024, the regulation of momelotinib (Omjjara) was approved by the European Commission. It is the first agent for the treatment of adult patients with disease-related splenomegaly or symptoms and moderate to severe anemia including patients with primary myelofibrosis, post-polycythemia vera (PV) myelofibrosis, or post–essential thrombocythemia (ET) myelofibrosis and who are JAK inhibitor naive or have treatment history with ruxolitinib (Jakafi). The approval of the once-a-day, oral JAK1/JAK2, and ACVR1 inhibitor was based on data from the phase 3 MOMENTUM trial (NCT04173494) and data from a subpopulation of patients with moderate to severe anemia from the phase 3 SIMPLIFY-1 trial (NCT01969838).

Myelofibrosis Market Trends

Myelofibrosis Market Segmentation

Myelofibrosis Market Share

Market Share by Type to Undergo Growth

The market segmentation by type includes primary myelofibrosis and secondary myelofibrosis. The market share is dominated by primary myelofibrosis due to its higher prevalence and increased focus of researchers on developing targeted therapies for the condition. Primary myelofibrosis is a chronic condition with significant unmet needs, driving demand for effective treatments and diagnostics. The market dominance can also be attributed to the increasing availability of novel therapies such as JAK inhibitors, which are primarily indicated for the condition. Secondary myelofibrosis is quite uncommon and often occurs as a progression from myeloproliferative disorders.

Target Therapy to Lead the Share Based on Treatment Type

On the basis of treatment type, the segmentation includes target therapy, chemotherapy, stem cell transplant, and others. The market share is expected to be led by the targeted therapy due to its ability to specifically address the genetic mutations that support the disease. JAK inhibitors are a key component of targeted therapy and are effective in managing symptoms and improving patient outcomes. Targeted therapies offer a better safety profile and fewer side effects compared to traditional chemotherapy. These treatments are more suitable for long-term treatments which are prominent in managing chronic conditions like myelofibrosis. The continuous development and approval of new targeted drugs is boosting the market dominance.  

Myelofibrosis Market Analysis by Region

The United States dominates the regional market share due to the presence of a well-established healthcare infrastructure, high prevalence of the condition, and continuous research and development activities by the researchers. With the presence of an advanced healthcare infrastructure, the region experiences increased adoption of advanced technologies and the development of effective therapies. The presence of leading market players and access to cutting-edge diagnostic and treatment options contribute to the dominance of the United States. The market dominance is further fuelled by the increased awareness of myelofibrosis and healthcare policies available in the region to support the treatment of the condition. Heavy investments by the market players in the development of effective treatment therapies for myelofibrosis are propelling overall market growth in the region.

Leading players in the Myelofibrosis Market

Key Questions Answered in the Myelofibrosis Market

• What was the myelofibrosis market value in 2024? 
• What is the myelofibrosis market forecast outlook for 2025-2034? 
• What are the regional markets covered in the EMR report? 
• What is the market segmentation based on type? 
• What is market segmentation based on treatment type? 
• How is the market segmented based on the diagnosis?
• Who are the end-users in the market? 
• What are the major factors aiding the myelofibrosis market demand?  
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?  
• Which regional market is expected to lead the market share in the forecast period?  
• Which country is expected to experience expedited growth during the forecast period?  
• What are the major myelofibrosis market trends?
• Which technology is expected to dominate the market? 
• Which type will lead the market segment?
• Which treatment type will dominate the market share? 
• Which diagnosis is poised to lead the market share?
• Which end-user will lead the market?
• Who are the key players involved in the myelofibrosis market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?